Last updated 18 days ago

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

618 patients around the world
Available in Spain, Brazil, Argentina, United States
Novo Nordisk A/S
618Patients around the world
This study is for people with
Renal disease
Chronic kidney disease
Diabetes
Diabetes mellitus type 2
Obesity
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLast newsStudiesInterviewsTestimonies
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy